Trial
NCT01717898
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Charles Ryan
Collaborators
Novartis Pharmaceuticals
Condition
Castrate-resistant Prostate Cancer
Intervention
BEZ235
Why stopped
Dose limiting toxicities on lowest dose level
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-03-27